The clinical question remains as to whether stress is a trigger—or at least an exacerbating factor—in psoriasis and if so, how this should influence treatment approaches.
Investigators examined the efficacy of brodalumab, an interleukin-17 receptor-A antagonist to treat moderate to severe psoriasis in patients who had no clinical response with prior anti-interleukin-17A therapies.
Investigators examined the scientific opinions of dermatologists and hospital pharmacists to reach a consensus about the effect, causes, and best strategies and interventions related to improved drug persistence in patients with psoriasis in Spain.
Investigators evaluated the effect of neutralizing antibodies or treatment-emergent antidrug antibodies on clinical efficacy and safety of secukinumab in patients with moderate to severe plaque psoriasis.
For patients with psoriasis treated with systemic medications, the risk for serious infection is reduced for new users of apremilast, etanercept, and ustekinumab versus methotrexate.
Investigators measured the survival rates of biologic therapies in children with psoriasis in real-life conditions, identified factors associated with choice of biologic therapy, and analyzed severe adverse events.
According to the results of an observational cohort study, the risk of serious infection may vary significantly among systemic therapies used in the treatment of psoriasis.
